Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16193530 | 0.85 | TSHR (0.36) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| SCHEMBL15539193 | 0.82 | MAPT (0.38) | TSHRMAPTHTR2ACYP1A2FABP5 | |
| SCHEMBL13723797 | 0.80 | KMT2A (0.35) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| SCHEMBL25373589 | 0.79 | ALDH1A1 (0.41) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| SCHEMBL16242267 | 0.79 | KMT2A (0.40) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| SCHEMBL1639593 | 0.78 | HTR2A (0.38) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| SCHEMBL1198306 | 0.78 | HTR2A (0.38) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| SCHEMBL17454912 | 0.78 | HTR2A (0.46) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| Hydrochloric Acid SCHEMBL31031926 | 0.77 | HTR2A (0.44) | TSHRMAPTHTR2ACYP1A2FABP7 | |
| SCHEMBL16194095 | 0.77 | HDAC1 (0.38) | TSHRMAPTHTR2ACYP1A2FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333217-B2 | Inhibitors of human EZH2, and methods of use thereof | Epizyme, Inc. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
| US-20150141362-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | Epizyme, Inc. | 2015-05-21 | — | — | US | disclosed |
| EP-2646455-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2614369-A2 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | Epizyme, Inc. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012034132-A2 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2004005328-A2 | PEPTIDOMIMETIC COMPOUND USEFUL AS INHIBITOR OF INTEGRINS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | TSHR 4851/4885MAPT 2334/4885HTR2A 4739/4885 |
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | TSHR 3593/4885MAPT 4156/4885HTR2A 3693/4885 |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | TSHR 3496/4885MAPT 1361/4885HTR2A 2852/4885 |
| US-20150141362-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | TSHR 3385/4885MAPT 4075/4885HTR2A 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.